CARB-X awards up to $18M to GSK for two vaccines

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) awarded up to $18 million to GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH) to develop new vaccines for two different illnesses.

One is a vaccine for Group A streptococcus infections, or as it is commonly known, strep throat. This award is worth up to $8.2 million, plus up to an additional $4.2 million if the project meets certain milestones.

The other is for infections caused by Salmonella enterica, which causes Invasive nontyphoidal salmonellosis (iNTS) disease and typhoid fever. These conditions cause significant health challenges for children, primarily in sub-Saharan African countries. Salmonella enterica is listed by the World Health Organization (WHO) as among those bacteria that pose the greatest threat to human health. The CARB-X award is for $2.2 million to support the development of this new vaccine, with up to $4 million more if milestones are met.

Currently, there no vaccines available for either of these diseases. Both of the GSK vaccine projects are in the preclinical phase of development.

“Vaccines are powerful weapons in the global fight against antibiotic-resistant bacteria. Vaccines not only prevent infections, they also reduce the need for antibiotics, helping to curb the spread of drug resistance,” Erin Duffy, R&D Chief of CARB-X, a non-profit global partnership led by Boston University that is dedicated to supporting the development of therapeutics, preventatives, and diagnostics to address antibiotic-resistant bacterial infections.

GSK’s strep throat vaccine aims to reduce the incidence and severity of Strep A infections, while the salmonella vaccine could prevent death and contribute to reduced antibiotic consumption.

“As part of GSK’s overall Global Health approach, GVGH is dedicated to working with partners to develop effective and affordable vaccines that protect vulnerable communities against some of the most prevalent diseases causing high morbidity and mortality in developing countries, Francesco Berlanda Scorza, GVGH Director, said. “Thanks to CARB-X support, we have the opportunity to study and advance innovative vaccines against Salmonellosis and Group A Streptococcus, and contribute to the fight against antimicrobial resistance (AMR).”

The World Health Organization estimates that 700,000 people die each year from antibiotic-resistant infections, including 35,000 in the United States and 33,000 in Europe. Since 2016, CARB-X has announced 80 awards worth more than $299.8 million.

Dave Kovaleski

Recent Posts

DHS Report: Environment unlikely to affect transmissibility of SARS-COV-2 variants

New research from the Department of Homeland Security (DHS) Science and Technology Directorate (S&T) has…

22 hours ago

CDC funds target COVID-19 vaccine program expansion

The Centers for Disease Control and Prevention (CDC) has earmarked $3 billion to 64 jurisdictions…

22 hours ago

Lawmakers urge refrain from Iran approach

A group of lawmakers recently forwarded correspondence to President Joe Biden to encourage a reset…

22 hours ago

WHO labels AstraZeneca COVID-19 vaccine blood clot issues rare, but worth continued study

An assessment by the COVID-19 subcommittee of the World Health Organization (WHO) Global Advisory Committee…

22 hours ago

Senators urge Biden administration to fund secure 5G networks

U.S. Sens. Dianne Feinstein (D-CA) and Mark Warner (D-VA) joined a group of bipartisan Congress…

2 days ago

This website uses cookies.